Tesamorelin

Description

DESCRIPTION

Tesamorelin is a synthetic analogue of human Growth Hormone–Releasing Hormone (GHRH), engineered with an N‑terminal trans‑3‑hexenoic acid modification to improve molecular stability and resistance to enzymatic breakdown. Laboratory research evaluates its ability to stimulate pulsatile GH release, increase IGF‑1, and influence metabolic and body‑composition pathways. Studies explore its mechanistic roles in adipose‑tissue modeling, hepatic signaling, endocrine regulation, and GH/IGF‑1 axis dynamics.

LYOPHILIZED PEPTIDES

This peptide is supplied as a sterile, freeze‑dried (lyophilized) powder to maintain purity, structural integrity, and long‑term stability. No fillers or excipients are added.

RESEARCH APPLICATIONS

1 — Visceral Adipose Tissue (VAT) Modeling

Tesamorelin is widely used in research involving VAT reduction, GH‑mediated lipolytic signaling, and metabolic remodeling pathways. Controlled studies investigate its influence on central fat compartments and endocrine‑regulated metabolic markers.

(References: NEJM VAT research — https://pubmed.ncbi.nlm.nih.gov/20818885/, JAMA metabolic modeling — https://pubmed.ncbi.nlm.nih.gov/21304038/ )

2 — GH / IGF‑1 Axis & Endocrine Studies

Research evaluates Tesamorelin’s selective stimulation of GHRH receptors, pulsatile GH release, and downstream IGF‑1 modulation. Comparative studies differentiate endogenous vs exogenous GH signaling using this peptide as a model compound.

(References: PubMed—https://pubmed.ncbi.nlm.nih.gov/22392532/, Nature—https://www.nature.com/articles/s41582-020-00420-0 )

3 — Hepatic Fat, Lipid Regulation & Metabolic Signaling

Tesamorelin has been used in liver‑fat modeling studies, exploring its effects on hepatic triglyceride turnover, steatosis pathways, and metabolic‑liver biomarkers. These models provide insight into GH‑driven hepatic metabolic regulation.

(References: ScienceDirect—https://www.sciencedirect.com/science/article/pii/S1550413119305336, PubMed—https://pubmed.ncbi.nlm.nih.gov/36638174/ )

4 — Body‑Composition, Muscle, & Energy‑Balance Research

Studies explore Tesamorelin’s potential influence on muscle composition, resting‑energy expenditure, and body‑composition pathways through GH‑mediated protein‑synthesis signaling.

(References: MDPI—https://www.mdpi.com/1422-0067/24/3/2341, PubMed—https://pubmed.ncbi.nlm.nih.gov/36971244/ )

SPECIFICATIONS

Property | Details

Peptide Name | Tesamorelin

Amino Acid Sequence | trans‑3‑hexenoic acid–Tyr–Ala–Asp–Ala–Ile–Phe–Thr–Asn–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Asp–Gln–Leu–Lys–Glu–Lys–Gln–Ala–Gly–Ala–Leu–Arg–Ala–Arg–Leu–NH₂

CAS Number | 218949‑48‑5

Molecular Formula | C221H366N72O67S

Molecular Weight | ~5135.8 g/mol

Appearance | White to off‑white lyophilized powder

Purity | ≥ 99% (HPLC verified)

Solubility | Soluble in bacteriostatic/sterile water

Storage | Store dry at −20 °C; refrigerate ≤ 30 days after reconstitution

Usage | Laboratory research only

Research Data & References

– VAT & metabolic modeling (NEJM): https://pubmed.ncbi.nlm.nih.gov/20818885/

– GH/IGF‑1 axis studies: https://pubmed.ncbi.nlm.nih.gov/22392532/

– Hepatic fat & metabolic pathways: https://pubmed.ncbi.nlm.nih.gov/36638174/

Disclaimer — Research Use Only

All information presented herein is intended solely for laboratory and educational research. These materials are not approved for human or veterinary use, nor for diagnostic or therapeutic application. Descriptions of biochemical activity are provided for informational context only and must not be interpreted as medical advice. Researchers are expected to handle all compounds in compliance with local regulations and institutional safety standards. EOC Labs supports responsible, ethical, and compliant scientific inquiry.